TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Estrogen in the Prevention of Atherosclerosis Trial
Brief Summary: The purpose of this study is to determine the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease (CVD).


Options:
A: Postmenopausal women with angiographically-documented coronary disease. Approximately 70 percent minority
B: Inclusion Criteria:

* Women aged 45-58 years with an intact uterus
* Three to 24 month past last menstrual bleeding
* Hysterectomised women aged 45-52 years and having elevated FSH

Exclusion Criteria:

* Metaboliv bone disease including osteoporosis defined as non-traumatic vertebral fractures on X-ray
* Current estrogen use or estrogen use within the past three month
* Current or past treatment with glucocorticoids for more than 6 month
* Current or past malignancy
* Newly diagnosed or uncontrolled chronic disease
* Alcohol or drug addiction
C: Inclusion Criteria:

* Postmenopausal female (serum estradiol less than 20 pg/ml)
* 46 to 80 years old
* Fasting LDL-C levels 130 to 210 mg/dL
* Triglyceride levels less than 400 mg/dL
* Current non-smoker

Exclusion Criteria:

* Clinical evidence of cardiovascular disease
* HDL-C level less than 30 mg/dL
* Fasting blood glucose greater than 200 mg/dL
* Previous hormonal replacement therapy (non-contraceptive) over 10 years duration and/or current use within 1 month
* Uncontrolled hypertension
* Untreated thyroid disease
* Renal insufficiency
* Clinical evidence of congestive heart failure
* Life threatening disease with prognosis less than 5 years
* Alcohol intake greater than 5 drinks per day (1 drink = 1 1/2 oz distilled spirits, 4 oz wine, or 12 oz beer) or substance abuse (intravenous drug abuse, cocaine use)
* History of estrogen dependent cancer or detected at screening or any other disorder precluding use of ERT
* Hot flashes greater than 5 per day which interfere with daily activity and preclude randomization to placebo.
D: Postmenopausal women ages 50 to 79.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Maternal Micronutrient Supplementation to Reduce Low Birth Weight and Infant and Maternal Morbidity in Rural Nepal
Brief Summary: The purpose of this study was to determine the effects of providing supplements containing alternative combinations of micronutrients during pregnancy on birth weight and other infant and maternal health and nutritional outcomes in a rural area of Nepal.


Options:
A: Inclusion Criteria:

* Married women of reproductive age identified as a new pregnancy using a urine test

Exclusion Criteria:

* Menopausal or sterilized woman or currently already pregnant or breastfeeding an infant \<9 months of age
B: RCT Inclusion Criteria:

* Gestational age 9 -16 weeks
* Singleton pregnancy
* Nulliparous

Observational Inclusion Criteria:

* Women randomized to the RCT
* Gestational age 9 - 12 wks

Exclusion Criteria RCT and Observational:

* BP \>= 135/85
* Proteinuria
* History or current use of anti-hypertensive medication or diuretics
* Use of vitamins C \> 150 mg and/or E \> 75 IU per day
* Pregestational diabetes
* Current pregnancy is a result of in vitro fertilization
* Regular use of platelet active drugs or non-steroidal anti-inflammatory drugs (NSAIDS)
* Known fetal abnormalities
* Documented uterine bleeding within a week of screening
* Uterine malformations
* History of medical complications
* Illicit drug or alcohol abuse during current pregnancy
* Intent to deliver elsewhere
* Participating in another interventional study
C: Inclusion Criteria:

All the women of child-bearing age (15-44 years) living in the study area (4 100) will be visited monthly to assess early pregnancy and will be invited to participate in the trial.

Exclusion Criteria:

Will be excluded from the study women :

* planning to move outside the district within the 2 years following the start of the trial.
* regularly using a contraceptive method.
* already pregnant at the start of the trial.
D: Inclusion Criteria:

* Women with cleft lip with/out palate (CLP), 16 to 45 years of age registered at the study clinics in Brazil or Women (16 to 45 years of age) with at least one natural child of any age with CLP registered at the study clinics.
* Women must reside in the catchment area of the study, which includes the states where the study clinics are located and surrounding states.

Exclusion Criteria:

* Consanguineous couples (up to third degree, i.e. first cousins or closer).
* Pregnany at the time of recruitment. Women will be recontacted later at an appropriate time for participation in the study.
* Couples either one of which have been sterilized.
* Taking any form of seizure medication.
* Planning to move outside of the study catchment area within the next year.
* B12 deficiency (\<174 pg/mL or 129.15 pmol/L).
* Being allergic to folic acid.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Maternal Micronutrient Supplementation to Reduce Low Birth Weight and Infant and Maternal Morbidity in Rural Nepal
Brief Summary: The purpose of this study was to determine the effects of providing supplements containing alternative combinations of micronutrients during pregnancy on birth weight and other infant and maternal health and nutritional outcomes in a rural area of Nepal.


Options:
A: Inclusion Criteria:

All the women of child-bearing age (15-44 years) living in the study area (4 100) will be visited monthly to assess early pregnancy and will be invited to participate in the trial.

Exclusion Criteria:

Will be excluded from the study women :

* planning to move outside the district within the 2 years following the start of the trial.
* regularly using a contraceptive method.
* already pregnant at the start of the trial.
B: Inclusion Criteria:

- HIV-positive pregnant women who are between 12 and 27 weeks gestation who intend to stay in Dar es Salaam until delivery.
C: Inclusion Criteria:

* All women of reproductive age (15 to 45 years) who are permanent residents in any of the 4 districts in rural Ghana (Kintampo, Wenchi, Techiman, and Nkoranza)

Exclusion Criteria:

* There will be no exclusions to participation, except for women who are unable to give their informed consent to join the study
D: Inclusion Criteria:

* Married women of reproductive age identified as a new pregnancy using a urine test

Exclusion Criteria:

* Menopausal or sterilized woman or currently already pregnant or breastfeeding an infant \<9 months of age

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Maternal Micronutrient Supplementation to Reduce Low Birth Weight and Infant and Maternal Morbidity in Rural Nepal
Brief Summary: The purpose of this study was to determine the effects of providing supplements containing alternative combinations of micronutrients during pregnancy on birth weight and other infant and maternal health and nutritional outcomes in a rural area of Nepal.


Options:
A: Inclusion Criteria:

* Singleton, live born infants born to HIV- negative women
* Mothers will need to have registered for pre-natal care before 34 weeks gestation
* intend to stay in Dar es Salaam for until delivery and 18 months thereafter.

Exclusion Criteria:

* infants born with multiple congenital abnormalities
B: Inclusion Criteria:

* All available children who received iron and zinc study during infancy

Exclusion Criteria:

* Neurological disorder
C: Inclusion Criteria:

* Married women of reproductive age identified as a new pregnancy using a urine test

Exclusion Criteria:

* Menopausal or sterilized woman or currently already pregnant or breastfeeding an infant \<9 months of age
D: Inclusion Criteria:

* Born at term of non-low birth weight
* Free of major malformations, genetic abnormalities or health problems associated with developmental delays
* Planning to remain in study area for one year
* In good general health

Exclusion Criteria:

* Low birth weight
* Non-term delivery
* Vision or hearing problems
* Anemia

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Comparison of Aerobic Versus Resistance Exercise Training in Enhancing Quality of Life in Early Stage Breast Cancer Survivors Receiving Chemotherapy: A Multi-Centre Randomized Trial
Brief Summary: The purpose of this study is to compare the effects of two different types of exercise, aerobic exercise training (AET) and resistance exercise training (RET), on quality of life (QoL) in early stage breast cancer survivors receiving chemotherapy. It is hypothesized that both AET and RET would have beneficial effects on QoL.


Options:
A: Inclusion Criteria:

* Have been diagnosed with breast, lung or colorectal cancer in the previous 8 weeks
* Are to receive oncologic care at the Albert Einstein Cancer Center (AECC)
* Have a life-expectancy of at least 6 months
* Are either English- or Spanish-speaking
* Do not practice yoga regularly (\> 1 month)
* Receive medical clearance by oncologic personnel on the study

Exclusion Criteria:

* Eastern Cooperative Oncology Group performance status \>= 3
* Existence of any of the following:

  * Seizure disorder
  * Musculoskeletal conditions
  * Heart problems
  * Major psychiatric disorder
B: Inclusion Criteria:

* histologically confirmed primary breast cancer, stage I-III, after lumpectomy or mastectomy, indication for adjuvant radiotherapy
* BMI: 18-40
* ability to understand and follow the study protocol

Exclusion Criteria:

* contraindication for exercise
* participation in the BEATE trial or another systematic resistance or relaxation training
C: Inclusion Criteria:

* breast cancer patient after lumpectomy or mastectomy, stage I-III
* adjuvant chemotherapy
* BMI at least 18

Exclusion Criteria:

* contraindication for exercise
* radiotherapy during intervention period
D: Inclusion Criteria:

* Breast cancer early stage I -IIIA
* Completed axillary surgery
* Scheduled to receive adjuvant chemotherapy for 9 - 24 weeks
* Approval of the treating oncologist
* Able to understand and provide written informed consent in English or French (Ottawa)
* 18+ years of age
* No uncontrolled hypertension, cardiac illness, psychiatric condition
* No contraindication to exercise as determined by a fitness test

Exclusion Criteria:

* Pregnant.
* Unwilling to accept randomization.
* Any medical condition that would be a contraindication to exercise. The clinicians will make this decision.
* Unwilling to travel to/participate in the exercise program as defined by the protocol.
* Previous chemotherapy (previous cancer is NOT an exclusion criteria).
* Cancer recurrence.
* Planned/known absence of greater than 2 weeks during the intended study period.
* Previous therapy for known breast cancer.
* Those who have had TRAM (i.e., Transabdominal Rectus Abdominus Muscle Reconstructive Surgery) done.
* Moderate lymphedema (\>20% or \>200mL difference between the affected arm and the unaffected arm).

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Proactive Smoking Cessation for Adolescents
Brief Summary: The primary goal of the Hutchinson Study of High School Smoking, a group-randomized trial conducted by the Fred Hutchinson Cancer Research Center in partnership with 50 Washington State high schools, is to develop and evaluate an innovative proactive smoking cessation intervention, based upon Motivational Interviewing (MI) and Cognitive Behavioral Skills Training (CBST), for its effectiveness in reaching teen smokers and helping them succeed in quitting smoking. A positive finding would have significant implications for reducing youth smoking and, ultimately, improving the nation's health.


Options:
A: Inclusion Criteria:

* Aged 16 and older
* Current smoker: Willing to quit smoking within the next 12 weeks
* Having a regular access to Internet
* Having a personal e-mail address
* Having a personal mobile cell phone with a Danish number
* Given informed consent
* Can read and understand Danish

Exclusion Criteria:

* Less than 16 years of age
* No personal e-mail address
* No personal mobile cell phone
* Not able to give informed consent
B: Inclusion Criteria:

* All high school juniors enrolled in a participating high school who reported on their baseline survey that they smoked once a month or more; and a selected sample of nonsmoker respondents (former smokers and never smokers with close friends who smoke)
* Written or verbal parental consent required for intervention participation by students under age 18

Exclusion Criteria:

* Enrolled in participating school at time of baseline survey, but not developmentally able to independently complete the baseline survey
* Not able to understand or speak English sufficiently to complete informed consent for telephone counseling
* Foreign exchange students
C: Inclusion Criteria:

* Self-identified as first-generation Korean American
* Age 40 to 65 years of age
* SBP≥140 or DBP≥90mmHg on HBP medication
* resident of Greater Baltimore census tracts
* Written consent to participate in the screening/eligibility visit
* SBP≥140 or DBP≥90mmHg at the KRC HBP verification visit
* Written consent to participate in the clinical trial:agreeing to participate in study data collection procedures, receiving HBP education, using HBPMT, and permitting contact with their own medical care provider.

Exclusion Criteria:

* Acute and/or terminal condition precluding participation such as terminal cancer or acute myocardial infarction
* Psychiatric diagnosis precluding participation such as schizophrenia and cognitive impairment measured by self-report, chart review, or clinical assessment.
D: Inclusion Criteria:

* Pregnant women
* current cigarette smoker (smoked \>1 cigarette in the past 7 days)
* 18 years old or older
* Willing to consider altering their smoking behavior during their pregnancy

Exclusion Criteria:

* More than 26 weeks' gestation at study entry
* No telephone access
* Not planning to live in New England for 1 year
* Unable to read and speak English

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Evaluation of Home-Based Management of Fever in Urban Ugandan Children
Brief Summary: The purpose of this study is to see if providing effective antimalarial treatment at home for parents/guardians to treat their children for malaria will lead to an improved health outcome compared to conventional healthcare.


Options:
A: Inclusion Criteria:

* Age 1 - 5 years
* Agreement of parents or guardians to provide informed consent
* Live in Mulago III Parish

Exclusion Criteria:

* History of any known serious chronic disease requiring frequent medical care (e.g. AIDS, sickle cell disease, malignancy)
* Intention to move from Kampala during the 13 month follow-up period
* History of serious side effects to study medications
* Weight \< 10 kg
* Severe malnutrition defined as a weight-for-height or height-for-age Z-score \< - 3
B: Inclusion Criteria:

* Fever
* Informed consent

Exclusion Criteria:

* Severe clinical manifestations, which require immediate referral
* Pregnancy
* Previous enrollment in the study within the last 28 days
C: Inclusion Criteria:

* Age between 6 months and 5 years
* Present with history of fever or reported fever
* Present with cough or difficult breathing

Exclusion Criteria:

* Age below 6 months and above 5 years
* Presence of signs and symptoms of severe illness
D: Inclusion Criteria:

1. Aged \<5 years
2. Weight \>5 kg
3. Suffering from acute uncomplicated P. falciparum malaria confirmed by RDT. Later microscopy using Giemsa-stained thick film will be made to ensure asexual parasite density of 2000 to 200 000 parasites/µL
4. Having a history of fever in the preceding 24 h
5. Able to ingest tablets orally
6. Willing and able to attend stipulated follow-up visits
7. With written informed consent from parent/guardian for children to participate in the trial.

Exclusion Criteria:

Presenting with any of the following "danger signs of severe malaria":

1. Convulsions (\>1 episode within previous 24 hours)
2. Lethargic/unconscious

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomised Trial to Compare the Efficacy and Safety of Intranasal Lorazepam and Intramuscular Paraldehyde in the Treatment of Convulsions in Children
Brief Summary: The purpose of this study is to evaluate intranasal lorazepam in paediatric status epilepticus. This is a potentially, more effective, safer and cheaper treatment for a common paediatric medical emergency compared to our present first line therapy intramuscular paraldehyde.


Options:
A: Inclusion Criteria:

* Children aged between 2 months and 12 years
* Presenting with generalised convulsions

Exclusion Criteria:

* Any child who had received an anticonvulsant agent within 1 hour of presentation
* Seizure stopped with rapid cooling or treatment of hypoglycaemia
* Features consistent with organophosphate poisoning, hepatic or hypertensive encephalopathy
B: Inclusion Criteria:

* Children presenting convulsing to the pediatric emergency or developing seizure while in casualty
* Age 6-14 years

Exclusion Criteria:

* Known hypersensitivity to any benzodiazepine
* Child has received any parenteral anti-convulsant within 1 hr prior to enrollment
* Presence of severe cardio-respiratory compromise or cardiac arrhythmias
* Presence of upper respiratory tract infection
* Presence of basal skull fracture causing cerebro-spinal fluid (CSF) rhinorrhea
C: Inclusion Criteria:

* Paramedics or reliable witnesses verify 5 minutes of either continuous seizure activity or of repeated convulsive seizure activity where the patient does not regain consciousness (operationally defined as meaningful speech or obeying commands) between seizures.
* Patient is still seizing at the time of paramedic treatment with study medications.
* Estimated weight equal to or greater than 13 kg.
* Subject to be transported to a RAMPART participating hospital.

Exclusion Criteria:

* Major trauma as the precipitant of the seizure
* Hypoglycemia (as defined by local EMS protocol or a glucose \< 60 mg/dL)
* Known allergy to midazolam or lorazepam
* Cardiac arrest or heart rate (HR) \<40 beats per minute
* Sensitivity to benzodiazepines
* Medical alert tag marked with "RAMPART declined"
* Prior treatment of this seizure with diazepam autoinjector as part of another study
* Known pregnancy
* Prisoners
D: Inclusion Criteria:

* Children seventeen years and under will be identified through a Pediatric Neurology clinic at Primary Children's Medical Center,
* Known seizure disorder, AND
* Either have or will be prescribed a rescue anti-epileptic (rectal diazepam, or Diastat) for home use by their neurologist.

Exclusion Criteria:

* The neurologist does not prescribe a rescue medication for home use,
* 18 years of age or older,
* They have absence seizures, OR
* They have been prescribed lorazepam for home use for seizure activity.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Aripiprazole in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Double Blind Placebo Controlled Trial
Brief Summary: There is a scarcity of clinical trials assessing the effects of medications in children with bipolar disorder. This study aims to assess the efficacy of Aripiprazole (a novel anti-psychotic drug) for the treatment of children and adolescents with bipolar disorder comorbid with ADHD. The study design is a 8-week randomized, double blind, parallel group trial. Patients were randomized to either aripiprazole or placebo.

The main hypotheses are:

1. Aripiprazole will significantly reduce maniac scores compared to placebo
2. Aripiprazole will significantly reduce ADHD scores compared to placebo


Options:
A: Inclusion Criteria:

* Men and women \> or = to 18 years of age meeting Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder, currently experiencing a manic or mixed episode with a history of one or more manic or mixed episodes or sufficient severity to require hospitalization and/or treatment with a mood stabilizer or antipsychotic.
B: Inclusion Criteria:

* Subjects with Bipolar I Disorder and a diagnosis of acute mania will be considered for this study.
C: Inclusion Criteria:

* Clinical diagnosis of bipolar I disorder, manic or mixed episode

Exclusion Criteria:

* First manic or mixed episode
* Allergic, intolerant, or unresponsive to lithium and valproate or to aripiprazole
* Participation in a previous clinical trial within the past month or ever participated in a trial with aripiprazole
D: Inclusion Criteria:

* Age: 8-17
* BD type I or II comorbid with ADHD
* Baseline score in the YMRS \> or = 20

Exclusion Criteria:

* IQ \< 70
* Pharmacologic treatment in the last month
* Pregnancy or absence of a contraceptive method in fertile girls
* Diagnoses: pervasive development disorder, schizophrenia, drug abuse or dependency
* Risk of suicide or homicide
* Clinical condition that might interfere in the study
* Known sensibility to aripiprazole

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Misoprostol for the Treatment of Primary Postpartum Hemorrhage
Brief Summary: The purpose of this study is to test whether misoprostol is as effective as oxytocin for treating primary postpartum hemorrhage (PPH) with uterine atony as the suspected cause in two circumstances: 1) where women have received prophylactic uterotonics in the third stage of labor; and 2) where no prophylactic uterotonics have been given in the third stage of labor.


Options:
A: Inclusion Criteria:

* Vaginal delivery
* Postpartum hemorrhage due to suspected uterine atony
* Depending on study group: administration of prophylactic uterotonics in third stage of labor

Exclusion Criteria:

* Known allergy to misoprostol or other prostaglandin
* C-section for current delivery
B: Inclusion Criteria:

* Women who deliver at home with a study TBA present.
* Women must be willing and able to provide informed consent
* Women must agree to participate in a follow up interview
* Women must agree to have pre and post-partum haemoglobin taken

Exclusion Criteria:

* If the woman does not meet any of the above outlined inclusion criteria
C: Inclusion Criteria:

* Women with atonic PPH.

Exclusion Criteria:

* Gestational age \<37 weeks.
* Hypertension.
* Preeclampsia.
* Cardiac, renal or liver diseases
* Epilepsy.
* Known hypersensitivity to Carbetocin
D: Inclusion Criteria:

* pregnant with a fetus \>/=24 weeks gestational age
* non-emergent cesarean delivery
* postpartum hemorrhage deemed the result of uterine atony

Exclusion Criteria:

* non-English speaking patients requiring an interpreter
* any hypertensive disorder
* cardiovascular disease
* asthma
* refusal of transfused blood products
* coagulopathy or abnormal coagulation lab values
* hypersensitivity to methylergonovine maleate or 15-methyl prostaglandin

Answer: A